An EEG Study of Intravenous Ketamine for Major Depression Disorder
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
There are many common pharmacological treatments for major depression disorder (MDD), however
the efficacy of these drugs often fails in severe cases. Intravenous (IV) administered
ketamine may offer the potential for remission of the symptoms in patients with MDD; however
it has not yet been approved by FDA for this purpose. This study will make use of an
electroencephalography (EEG) machine to measure the brain's activity and response while the
IV ketamine is being delivered. The objective of this study is to characterize the change in
EEG response of patients with MDD, during and 4 weeks after a course of IV ketamine
infusions.